Micrornas in the pathobiology of osteosarcoma

Jyotika Varshney, Subree Subramanian

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Osteosarcoma is the most common primary bone malignancy affecting children, adolescents and young adults. Around 30% of patients with localized osteosarcoma and 70% of patients with metastasis will experience treatment failure within 5 years of diagnosis. Such a dismal outcome has remained static for the past 20 years leading to an urgent need to identify novel targets and therapeutic agents that will improve patients overall survival and minimize immediate and long-term side effects of current chemotherapeutic agents. Additionally, osteosarcoma is commonly found in canines, with approximately 10,000 new cases each year in the US. The complex biology of osteosarcoma and tumor heterogeneity makes it very difficult to identify effective actionable targets and therapeutic agents. This chapter will highlight the recent developments in our basic understanding of microRNA mediated gene regulations in osteosarcoma and discuss the potential for development of microRNA-based prognostic biomarkers. Further, this chapter will analyze the recent development of preclinical evaluation of a novel agent Minnelide in the treatment of osteosarcoma and emphasize the prospects for combinatorial drug treatment in osteosarcoma.

Original languageEnglish (US)
Title of host publicationOsteosarcoma
Subtitle of host publicationSymptoms, Diagnosis and Treatment Options
PublisherNova Science Publishers, Inc.
Pages165-200
Number of pages36
ISBN (Electronic)9781633210578
ISBN (Print)9781633210523
StatePublished - Jul 1 2014

Fingerprint

Osteosarcoma
MicroRNAs
Therapeutics
Treatment Failure
Canidae
Young Adult
Biomarkers
Neoplasm Metastasis
Bone and Bones
Survival
Pharmaceutical Preparations
Genes
Neoplasms

Cite this

Varshney, J., & Subramanian, S. (2014). Micrornas in the pathobiology of osteosarcoma. In Osteosarcoma: Symptoms, Diagnosis and Treatment Options (pp. 165-200). Nova Science Publishers, Inc..

Micrornas in the pathobiology of osteosarcoma. / Varshney, Jyotika; Subramanian, Subree.

Osteosarcoma: Symptoms, Diagnosis and Treatment Options. Nova Science Publishers, Inc., 2014. p. 165-200.

Research output: Chapter in Book/Report/Conference proceedingChapter

Varshney, J & Subramanian, S 2014, Micrornas in the pathobiology of osteosarcoma. in Osteosarcoma: Symptoms, Diagnosis and Treatment Options. Nova Science Publishers, Inc., pp. 165-200.
Varshney J, Subramanian S. Micrornas in the pathobiology of osteosarcoma. In Osteosarcoma: Symptoms, Diagnosis and Treatment Options. Nova Science Publishers, Inc. 2014. p. 165-200
Varshney, Jyotika ; Subramanian, Subree. / Micrornas in the pathobiology of osteosarcoma. Osteosarcoma: Symptoms, Diagnosis and Treatment Options. Nova Science Publishers, Inc., 2014. pp. 165-200
@inbook{18a64cc6edfd4268bd01b7163955b960,
title = "Micrornas in the pathobiology of osteosarcoma",
abstract = "Osteosarcoma is the most common primary bone malignancy affecting children, adolescents and young adults. Around 30{\%} of patients with localized osteosarcoma and 70{\%} of patients with metastasis will experience treatment failure within 5 years of diagnosis. Such a dismal outcome has remained static for the past 20 years leading to an urgent need to identify novel targets and therapeutic agents that will improve patients overall survival and minimize immediate and long-term side effects of current chemotherapeutic agents. Additionally, osteosarcoma is commonly found in canines, with approximately 10,000 new cases each year in the US. The complex biology of osteosarcoma and tumor heterogeneity makes it very difficult to identify effective actionable targets and therapeutic agents. This chapter will highlight the recent developments in our basic understanding of microRNA mediated gene regulations in osteosarcoma and discuss the potential for development of microRNA-based prognostic biomarkers. Further, this chapter will analyze the recent development of preclinical evaluation of a novel agent Minnelide in the treatment of osteosarcoma and emphasize the prospects for combinatorial drug treatment in osteosarcoma.",
author = "Jyotika Varshney and Subree Subramanian",
year = "2014",
month = "7",
day = "1",
language = "English (US)",
isbn = "9781633210523",
pages = "165--200",
booktitle = "Osteosarcoma",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Micrornas in the pathobiology of osteosarcoma

AU - Varshney, Jyotika

AU - Subramanian, Subree

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Osteosarcoma is the most common primary bone malignancy affecting children, adolescents and young adults. Around 30% of patients with localized osteosarcoma and 70% of patients with metastasis will experience treatment failure within 5 years of diagnosis. Such a dismal outcome has remained static for the past 20 years leading to an urgent need to identify novel targets and therapeutic agents that will improve patients overall survival and minimize immediate and long-term side effects of current chemotherapeutic agents. Additionally, osteosarcoma is commonly found in canines, with approximately 10,000 new cases each year in the US. The complex biology of osteosarcoma and tumor heterogeneity makes it very difficult to identify effective actionable targets and therapeutic agents. This chapter will highlight the recent developments in our basic understanding of microRNA mediated gene regulations in osteosarcoma and discuss the potential for development of microRNA-based prognostic biomarkers. Further, this chapter will analyze the recent development of preclinical evaluation of a novel agent Minnelide in the treatment of osteosarcoma and emphasize the prospects for combinatorial drug treatment in osteosarcoma.

AB - Osteosarcoma is the most common primary bone malignancy affecting children, adolescents and young adults. Around 30% of patients with localized osteosarcoma and 70% of patients with metastasis will experience treatment failure within 5 years of diagnosis. Such a dismal outcome has remained static for the past 20 years leading to an urgent need to identify novel targets and therapeutic agents that will improve patients overall survival and minimize immediate and long-term side effects of current chemotherapeutic agents. Additionally, osteosarcoma is commonly found in canines, with approximately 10,000 new cases each year in the US. The complex biology of osteosarcoma and tumor heterogeneity makes it very difficult to identify effective actionable targets and therapeutic agents. This chapter will highlight the recent developments in our basic understanding of microRNA mediated gene regulations in osteosarcoma and discuss the potential for development of microRNA-based prognostic biomarkers. Further, this chapter will analyze the recent development of preclinical evaluation of a novel agent Minnelide in the treatment of osteosarcoma and emphasize the prospects for combinatorial drug treatment in osteosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=84956831690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956831690&partnerID=8YFLogxK

M3 - Chapter

SN - 9781633210523

SP - 165

EP - 200

BT - Osteosarcoma

PB - Nova Science Publishers, Inc.

ER -